Who are Nalorphin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Codeine, Revivon, OXYCONTIN®, OxyContin, Ids-Ne-007.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nalorphine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Nalorphin — Competitive Intelligence Brief

Nalorphin (NALORPHINE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nalorphine. Area: Neuroscience.

marketed nalorphine Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Nalorphin (NALORPHINE). Nalorphine works by binding to the mu-type opioid receptor, which can either activate or block the receptor depending on the specific configuration of the molecule.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nalorphin TARGET	NALORPHINE		marketed	nalorphine	Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
Codeine	codeine phosphate	Generic (multiple manufacturers)	marketed	Opioid analgesic, Antitussive	Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor	1950-01-01
Revivon	DIPRENORPHINE		marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
OXYCONTIN®	OXYCONTIN®	Mundipharma (China) Pharmaceutical Co. Ltd	marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
OxyContin	oxycodone	Purdue Pharma	marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
Ids-Ne-007	ETORPHINE		marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-09 — OxyContin · 7771707 · Formulation · US
2030-12-10 — OxyContin · 9682075 · Formulation · US
2030-12-10 — OxyContin · 10004729 · Formulation · US
2030-12-10 — OxyContin · 10668060 · Formulation · US
2036-09-02 — OxyContin · 10188644 · Formulation · US
2036-09-02 — OxyContin · 9968598 · Formulation · US
2036-09-02 — OxyContin · 9737530 · Formulation · US
2036-09-02 — OxyContin · 10646485 · Formulation · US

Sponsor landscape (nalorphine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nalorphin — Competitive Intelligence Brief. https://druglandscape.com/ci/nalorphine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab